The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Neumora Therapeutics Reports 2025 Results and Positive NMRA-511 Clinical Data

Key Facts

1Neumora Therapeutics reported its financial results for the fourth quarter and full year 2025.

2New data for NMRA-511 supports a clinical effect comparable to pivotal studies of Rexulti and Auvelity.

Version History

10 additional sources confirmed this story

Neumora Therapeutics (NMRA) has announced its financial results for the fourth quarter and full fiscal year 2025, highlighting its year-end financial position. Alongside the earnings report, the company provided a significant clinical update regarding its drug candidate NMRA-511. New data indicates that NMRA-511 demonstrates a clinical effect comparable to results seen in pivotal studies for established treatments Rexulti and Auvelity. These findings support the drug's efficacy within a pre-specified patient population, marking a key milestone in its development pipeline. This progress underscores Neumora's competitive positioning within the biotechnology sector and its potential for future growth. Investors are closely monitoring these clinical advancements as the company continues to advance its therapeutic portfolio.